All-cause mortality in POAG and WODs groups
| Cox regression aHR (95% CI) | P values | |
| All-cause mortality | 2.11 (1.76 to 2.54) | <0.001* |
| Age, years | ||
| ≤64 | Reference | |
| 65–74 | 4.04 (3.18 to 5.13) | <0.001* |
| ≥75 | 11.64 (9.36 to 14.47) | <0.001* |
| Sex | ||
| Female | Reference | |
| Male | 1.31 (1.08 to 1.58) | <0.001* |
| Comorbidity | ||
| Diabetes | 1.06 (0.74 to 1.53) | 0.640 |
| Hypertension | 0.99 (0.77 to 1.27) | 0.882 |
| Hyperlipidaemia | 0.75 (0.53 to 1.06) | 0.018 |
| Modified CCI score | ||
| <1 | Reference | |
| 1–2 | 1.73 (1.38 to 2.16) | <0.001* |
| ≥3 | 3.02 (2.21 to 4.11) | <0.001* |
| Antihypertensive drugs | ||
| ACEIs and ARBs | 1.04 (0.82 to 1.32) | 0.651 |
| β-Blockers, non-selective | 1.10 (0.79 to 1.51) | 0.428 |
| β-Blockers, selective | 0.95 (0.71 to 1.26) | 0.605 |
| CCB | 1.31 (1.04 to 1.65) | 0.001* |
| Loop diuretics | 1.49 (1.09 to 2.04) | <0.001* |
| Antidiabetic drugs | ||
| Sulfonylurea | 1.51 (1.05 to 2.15) | 0.001* |
| Biguanides | 1.04 (0.74 to 1.47) | 0.734 |
| α-Glucosidase inhibitors | 1.33 (0.70 to 2.50) | 0.213 |
| Thiazolidinedione | 0.56 (0.25 to 1.29) | 0.051 |
| Meglitinide | 1.42 (0.69 to 2.93) | 0.177 |
| Insulin | 1.74 (1.17 to 2.58) | 0.001* |
| Aminoglycosides | 1.33 (1.04 to 1.70) | 0.001* |
| Statins | 1.19 (0.80 to 1.77) | 0.229 |
| Antiplatelet drugs | 0.95 (0.76 to 1.18) | 0.503 |
Adjusted for all covariates after propensity score matching (table 1).
*Denotes p<0.005 and was considered statistically significant.
ACEIs, ACE inhibitors; aHR, adjusted HR; ARBs, angiotensin II receptor blockers; CCB, calcium-channel blocker; CCI, Charlson Comorbidity Index; POAG, primary open-angle glaucoma; WODs, without ocular disorders.